| Returns | 1W : 3.6% , 1M : 8.9%,1Y : 111.8% |
| Peers & Returns | 1W | 1M | 1Y |
| FDC | 3.6% | 8.9% | 111.8% |
| SUN PHARMACEUTICAL INDUSTRIES | 5.5% | 0.2% | 19.7% |
| DRREDDYS LABORATORIES | 22% | 19% | 74.5% |
| DIVIS LABORATORIES | 5.7% | 5% | 95.2% |
| CIPLA | 11.8% | 5.8% | 60.7% |
| PIRAMAL ENTERPRISES | 3.2% | -4.2% | -28.5% |
| LUPIN | 12.2% | 10.5% | 36.7% |
| AUROBINDO PHARMA | 4.1% | -3.4% | 29.1% |
| TORRENT PHARMACEUTICALS | 2.7% | 2.1% | 66.1% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S PEG |
27.92 3.34 4.35 1.55 |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
82% 67% 66% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For Banking industry, Good = Ratio less than 13 Average = Ratio between 13 and 15 Bad = Ratio greater than 15 For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2019 2018 2017 Avg_3yrs |
0 0 0 - |
0 0 0 - |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As of : July 14,2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Parameter | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
-7.54% 87.51% 102.98% 54.93% |
-9.16% 55.66% 63.34% 73.34% |
| QtrlyTrend |
4
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Jun2020 | ||
